Alexandria Real Estate Equities (ARE) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Funds from Operations (FFO): $1.73 per share diluted as adjusted for Q2 2026; reaffirmed guidance for 2026 FFO per share at $6.40 (±$0.05).

Leasing Volume: 1,039,000 square feet in Q2, a 60% increase from the prior quarter and a 9% increase from the historical average.

Occupancy Rate: 86.9%, down 80 basis points from the previous quarter.

Same-Property Net Operating Income (NOI): Decreased by 10.6% year-over-year, with a cash basis decline of 8.6%.

Liquidity: $3.6 billion available; extended $5 billion credit facility to 2032.

2Strategic Updates and Business Highlights

Leasing Focus: 75% of leasing activity came from existing tenants; strong performance in life sciences (40% of leasing) and advanced technology (30%).

Development Pipeline: 1.4 million square feet under construction, 71% leased; focus on reducing capital expenditures in the $1.75 billion construction pipeline.

Dispositions: Targeting $2.9 billion in asset sales, with 46% completed or pending. Impairments of $222.5 million recognized, primarily related to land and lab conversion properties.

Tenant Base: 57% of annual rental revenue from investment-grade or publicly traded tenants; average remaining lease term of 7.7 years.

3Forward Guidance and Outlook

Leasing Projections: Anticipate 950,000 square feet of leasing in Q3 2026, with modest expirations over the next two quarters.

Capital Expenditures: Guidance for 2027 construction spending ranges from $1.15 billion to $1.65 billion, focusing on lease-up costs.

FFO Guidance: Tightened range for 2026 FFO per share, maintaining the midpoint at $6.40.

4Bad News, Challenges, or Points of Concern

Occupancy Decline: Occupancy fell 80 basis points, attributed to lease expirations and reclassification of properties.

Same-Property NOI Decline: Continued decrease in same-property performance, although improved from the previous quarter.

Market Conditions: Public biotech leasing remains sluggish, with only 6% of leasing volume coming from this sector. The company expressed concerns about regulatory challenges and the impact of potential Medicare for All policies.

Impairments: Significant impairments recorded, indicating challenges in the lab conversion market and oversupply in certain areas.

5Notable Q&A Insights

Leasing Strategy: Management emphasized flexibility in meeting market demands, including adjusting face rents and tenant improvement packages to attract advanced technology tenants.

Disposition Timing: Slight delays in disposition timing were noted, attributed to buyer financing processes and complexities in joint ventures.

Tenant Health: Positive momentum in private venture funding and IPOs was highlighted, but caution was advised regarding the overall health of biotech tenants.

Future Expectations: Management remains optimistic about leasing activity, particularly with mid-sized tenants returning to the market, while also preparing for potential challenges in 2027 lease expirations. Overall, ARE's Q2 2026 results reflect a mixed performance with strong leasing activity in certain sectors, but ongoing challenges in occupancy and same-property NOI. The company remains focused on strategic initiatives to enhance its portfolio and manage capital effectively.